로딩 중…
StockDiggingStockDigging

Damora Therapeutics Inc. Common Stock

DMRA· NASDAQ
$22.59-0.83%
2026-09-18

Financials

Valuation Metrics

Damora Therapeutics Inc. Common Stock's Market Cap is $1.39B. At end of 2025 it was $31M. Ranked #2267 of 3,121 in US market (top 73%), #908 of 1,463 on NASDAQ (top 62%), #169 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 64%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$1.39B
Revenue$0.00
Net Income$-263M
Total Assets$544M
Net Assets$516M
Employees7
Value
P/B2.69x
Profitability
ROE-50.93%
ROA-48.35%
Financial Health
Debt Ratio5.34%
Total Debt$0.00
Cash$541M
Current Ratio19.73x
Performance
1Y Return687.11%
1M Return-30.36%
From 52W High-41.06%
1Y MDD-72.38%
Trading
Volume2,357,989 shares
Trading Value$53M
Per Share
EPS$-4.27
BPS$8.38

Company Info

CEO Jennifer A. Jarrett
Employees 7
HQ Waltham, US

Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.